Literature DB >> 6149588

Low levels of somatostatin in human CSF mark depressive episodes.

H Agren, G Lundqvist.   

Abstract

Somatostatin-like immunoreactivity was measured in the cerebrospinal fluid (CSF) of 85 inpatients with current or recent episodes of major depressive disorders, diagnosed according to Research Diagnostic Criteria (RDC) as assessed with the Schedule for Affective Disorders and Schizophrenia (SADS). Several biopsychiatric tests were run during the same week of investigation. Results indicate low levels of CSF somatostatin to be a state marker for episodes of depression characterized by sad appearance, feelings of tiredness, insomnia, and subjective inability to acknowledge any external precipitants for the depression. CSF somatostatin was negatively related to platelet monoamine oxidase (MAO) activity; MAO activity appeared to account better for the degree of melancholic features than did somatostatin. The ratio between 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA) in CSF also correlated negatively with somatostatin. A positive relationship was noted between CSF xanthine and somatostatin. There was a highly significant curvilinear correlation between CSF somatostatin and serum TSH concentrations, but no correlations between CSF somatostatin and serum GH or prolactin, or with plasma cortisol before or after dexamethasone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149588     DOI: 10.1016/0306-4530(84)90003-9

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  12 in total

1.  Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder.

Authors:  J D Bremner; J Licinio; A Darnell; J H Krystal; M J Owens; S M Southwick; C B Nemeroff; D S Charney
Journal:  Am J Psychiatry       Date:  1997-05       Impact factor: 18.112

Review 2.  A role for the neuropeptide somatostatin in the neurobiology of behaviors associated with substances abuse and affective disorders.

Authors:  Stacey L Robinson; Todd E Thiele
Journal:  Neuropharmacology       Date:  2020-02-03       Impact factor: 5.250

Review 3.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

4.  Decrease in somatostatin-positive cell density in the amygdala of females with major depression.

Authors:  Gaelle Douillard-Guilloux; David Lewis; Marianne L Seney; Etienne Sibille
Journal:  Depress Anxiety       Date:  2016-08-24       Impact factor: 6.505

5.  Lack of effect of chronic carbamazepine on brain somatostatin in the rat.

Authors:  S R Weiss; T Nguyen; D R Rubinow; C J Helke; P K Narang; R M Post; D M Jacobowitz
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

6.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

7.  Somatostatin, neuronal vulnerability and behavioral emotionality.

Authors:  L C Lin; E Sibille
Journal:  Mol Psychiatry       Date:  2015-01-20       Impact factor: 15.992

Review 8.  Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?

Authors:  Li-Chun Lin; Etienne Sibille
Journal:  Front Pharmacol       Date:  2013-09-09       Impact factor: 5.810

9.  Characterization of GABAergic marker expression in the chronic unpredictable stress model of depression.

Authors:  Mounira Banasr; Ashley Lepack; Corey Fee; Vanja Duric; Jaime Maldonado-Aviles; Ralph DiLeone; Etienne Sibille; Ronald S Duman; Gerard Sanacora
Journal:  Chronic Stress (Thousand Oaks)       Date:  2017-08-03

Review 10.  Stress-Induced Morphological, Cellular and Molecular Changes in the Brain-Lessons Learned from the Chronic Mild Stress Model of Depression.

Authors:  Ahmad Raza Khan; Lili Geiger; Ove Wiborg; Boldizsár Czéh
Journal:  Cells       Date:  2020-04-21       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.